Mitraclip, an alternative to mitral valve regurgitation surgery from Abbott Park, Ill.-based Abbott Laboratories, demonstrated favorable 30-day and one-year outcomes, according to data from a postapproval study evaluating the safety and efficacy of the device. According to the results, 86.8 percent of patients had post-procedural mitral regurgitation of ≤2+ at one year.